The Effects of Dasatinib in Experimental Acute Respiratory Distress Syndrome Depend on Dose and Etiology

Cellular Physiology and Biochemistry

Volumn 36, Issue 4, 2015, Pages 1644-1658

  Oliveira, Gisele P ^a   Silva, Johnatas D ^a   Marques, Patricia S ^a   Gonçalves De Albuquerque, Cassiano F ^b   Santos, Heloísa L ^a   Vascocellos, Ana Paula ^a   Takiya, Christina M ^a   Morales, Marcelo M ^a   Pelosi, Paolo ^c   Mócsai, Attila ^d   De Castro Faria Neto, Hugo C ^b   Rocco, Patricia R M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF GENOA   (Italy)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Acute respiratory distress syndrome; Cytokines; Dasatinib; Histology; Lung mechanics; Toll like receptor 4

Indexed keywords

DASATINIB; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 10; INTERLEUKIN 6; TOLL LIKE RECEPTOR 4; VASCULOTROPIN; PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BREATHING RATE; COLLAGEN FIBER; CONTROLLED STUDY; DISTRESS SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNOHISTOCHEMISTRY; LIVER; LUNG LAVAGE; LUNG MECHANICS; MOUSE; NEUTROPHIL; NONHUMAN; PHYSICAL ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIDAL VOLUME; ANIMAL; C57BL MOUSE; DRUG EFFECTS; LUNG; PATHOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

ANIMALIA; ESCHERICHIA COLI; MUS;

ANIMALS; DASATINIB; INTERLEUKIN-10; INTERLEUKIN-6; LUNG; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; RESPIRATORY DISTRESS SYNDROME, ADULT; TOLL-LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84936966602     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430325     Document Type: Article

References (39)

1. Matthay MA, Ware LB, Zimmerman GA: The acute respiratory distress syndrome. J Clin Invest 2012;122:2731-2740.
2. Singurdsson MI, Sigvaldason K, Gunnarsson TS, Moller A, Singurdsson GH: Acute respiratory distress syndrome: nationwide changes in incidence, treatment and mortality over 23 years. Act Anaesthesiol Scand 2013;57:37-45.
3. Duan Y, Learoyd J, Meliton AY, Leff AR, Zhu X: Inhibition of Pyk2 blocks lung inflammation and injury in a mouse model of acute lung injury. Respiratory Research 2012;13:4.
4. Kim IK, Rhee CK, Yeo CD, Kang HH, Lee DG, Lee SH, Kim JM: Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Critical Care 2013;17:R114.
5. Choi JY, Park HJ, Lee YJ, Byun J, Youn YS, Choi JH, Woo SY, Kang JL: Upregulation of Mer receptor tyrosine kinase signaling attenuated lipopolysaccharide-induced lung inflammation. J Pharmacol Exp Ther 2013;344:447-458.
6. Zarbock A, Ley K: Protein tyrosine kinases in neutrophil activation and recruitment. Arch Biochem Biophys 2011;510:112-119.
7. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD: Second generation inhibi-tors of BCRABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-356.
8. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ: Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 2011;17:6905-6913.
9. Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ: Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014;3:e27589.
10. Rabenau KE, Dolan M, Yohe S, Ustun C: Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome. Cancer Genet 2014;207:109-110.
11. Futosi K, Németh T, Pick R, Vántus T, Walzog B, Mócsai A: Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;119:4981-4991.
12. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD: Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol 2009;37:1435-1444.
13. Berton G, Mócsai A, Lowell CA: Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol 2005;26:208-214.
14. Kovács M, Németh T, Jakus Z, Sitary C, Simon E, Futosi K, Botz B, Helyes Z, Lowell CA, Mócsai A: The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without direct role in leukocyte recruitment. J Exp Med 2014;11:1993-2011.
15. Menezes SL, Bozza PT, Neto HC, Laranjeira AP, Negri EM, Capelozzi VL, Zin WA, Rocco PR: Pulmonary and extrapulmonary acute lung injury: inflammatory and ultrastructural analyses. J Appl Physiol (1985) 2005;98:1777-1783.
16. Santos FB, Nagato LK, Boechem NM, Negri EM, Guimaraes A, Capelozzi VL, Faffe DS, Zin WA, Rocco PR: Time course of lung parenchyma remodeling in pulmonary and extrapulmonary acute lung injury. J Appl Physiol 2006;100:98-106.
17. Rocco PRM, Pelosi P: Pulmonary and extrapulmonary acute respiratory distress syndrome: myth or reality Curr Opin Crit Care 2008;14:50-55.
18. Araújo IM, Abreu SC, Maron-Gutierrez T, Cruz F, Fujisaki L, Carreira H Jr, Ornellas F, Ornellas D, Vieira-de-Abreu A, Castro-Faria-Neto HC, Muxfeldt Ab'Saber A, Teodoro WR, Diaz BL, Peres DaCosta C, Capelozzi VL, Pelosi P, Morales M, Rocco PR: Bone marrow-derived mononuclear cell therapy in experimental pulmonary and extrapulmonary acute lung injury. Crit Care Med 2010;38:1733-1741.
19. Maron-Gutierrez T, Silva JD, Asensi KD, Bakker-Abreu I, Shan Y, Diaz BL, Goldenberg RC, Mei SH, Stewart DJ, Morales MM, Rocco PR, Dos Santos CC: Effects of mesenchymal stem cell therapy on the time course of pulmonary remodelling depend on the etiology of lung injury in mice. Crit Care Med 2013;41:e319-e333.
20. Silva JD, Paredes BD, Araújo IM, Lopes-Pacheco M, Oliveira MV, Suhett GD, Faccioli LAP, Assis E, Castro-Faria-Neto HC, Goldenberg RCS, Capelozzi VL, Morales MM, Pelosi P, Xisto DG, Rocco PRM: Effects of bone marrow-derived mononuclear cells from healthy or acute respiratory distress syndrome donors on recipiente lung-injured mice. Crit Care Med 2014;42:e510-e524.
21. Bates JH, Rossi A, Milic-Emili J: Analysis of the behavior of the respiratory system with constant inspiratory flow. J Appl Physiol (1985) 1985;58:1840-1848.
22. Spieth PM, Silva PL, Garcia CS, Ornellas DS, Samary CS, Moraes L, Bentes M, Morales MM, Kasper M, Güldner A, Huhle R, Koch T, Pelosi P, de Abreu MG, Rocco PR: Modulation of stress versus time product during mechanical ventilation influences inflammation as well as alveolar epithelial and endothelial response in rats. Anesthesiology 2014;122:106-116.
23. Dias CM, Pássaro CP, Cagido VR, Einicker-Lamas M, Lowe J, Negri EM, Capelozzi VL, Zin WA, Rocco PR: Effects of undernutrition on respiratory mechanics and lung parenchyma remodeling. J Appl Physiol (1985) 2004;97:1888-1896.
24. Leite-Junior JH, Garcia CS, Souza-Fernandes AB, Silva PL, Ornellas DS, Larangeira AP, Castro-Faria-Neto HC, Morales MM, Negri EM, Capelozzi VL, Zin WA, Pelosi P, Bozza PT, Rocco PR: Methylprednisolone improves lung mechanics and reduces the inflammatory response in pulmonary but not in extrapulmonary mild acute lung injury in mice. Crit Care Med 2008;36:2621-2628.
25. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011;117:e75-e87.
26. Mealing S, Barcena L, Hawkins N, Clark J, Eaton V, Hirji I, Davis C: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: A systematic review and network metaanalysis. Exp Hematol Oncol 2013;19:5.
27. Ozanne J, Prescott AR, Clark K: The clinically-approved drugs Dasatinib and Bosutinib induce antiinflammatory macrophages by inhibiting the Salt-Inducible Kinases. Biochem J 2015;465:271-279.
28. El-Agamy DS: Nilotinib ameliorates lipopolysaccharide-induced acute lung injury in rats. Toxicol Appl Pharmacol 2011;253:153-160.
29. Lee HS, Moon C, Lee HW, Park EM, Cho MS, Kang JL: Src tyrosine kinases mediate activations of NF-B and integrin signal during lipopolysaccharide-induced acute lung injury. J Immunol 2007;179:7001-7011.
30. Kim IK, Rhee CK, Yeo CD, Kang HH, Lee DG, Lee SH, Kim JW: Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery. Crit Care 2013;17:R114.
31. Cai DS, Zhou H, Liu WW, Pei L: Protective effects of bone marrow-derived endothelial progenitor cells and Houttuynia cordata in lipopolysaccharide-induced acute lung injury in rats. Cell Physiol Biochem 2013;32:1577-1586.
32. Domenighetti G, Stricker H, Waldispuehl B: Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med 2001;29:57-62.
33. Galvao J, Davis B, Tilley M, Normando E, Duchen MR, Cordeiro MF: Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J 2014;28:1317-1330.
34. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): A potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008;61:365-376.
35. Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jüngel A, Zwerina J, Gay S, Schett G, Distler O, Distler JH: Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-2222.
36. Hu R, Xu H, Jiang H, Zhang Y, Sun Y: The role of TLR4 in the pathogenesis of indirect acute lung injury. Front Biosci 2013;18:1244-1255.
37. Yang Z, Deng Y, Su D, Tian J, Gao Y, He Z, Wang X: TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Lab Invest 2013;93:792-800.
38. Perros F, Lambrecht BN, Hammad H: TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. Respir Res 12: 125, 2011.
39. Albertine KH, Soulier MF, Wang Z, Ishizaka A, Hashimoto S, Zimmerman GA, Matthay MA, Ware LB: Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and acute respiratory distress syndrome. Am J Pathol 2002;161:1783-86.